PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST

Show other versions (1)

Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation. The article is devoted to apixaban use in clinical practice: examination before apixaban administration, c...

Full description

Bibliographic Details
Main Authors:	D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	new oral anticoagulants apixaban clinical pharmacology drug-drug interactions bleeding perioperative management
Online Access:	https://www.rpcardio.online/jour/article/view/154

Similar Items

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
by: D. A. Sychev, et al.
Published: (2015-09-01)

Practical aspects of apixaban use in clinical practice: continuing the theme
by: S. N. Bel'diev
Published: (2015-11-01)

THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016-06-01)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01)

Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
by: Omar A. Alshaya, et al.
Published: (2022-12-01)

APIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICE
by: L. N. ELISEEVA, et al.
Published: (2016-12-01)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis PatientsPlain Language Summary
by: Winston Wing-Shing Fung, et al.
Published: (2023-08-01)

Rectus sheath hematoma associated with apixaban
by: Kulothungan Gunasekaran, et al.
Published: (2017-08-01)

Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis
by: Benjamin J. R. Buckley, et al.
Published: (2022-06-01)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023-01-01)

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism
by: O. V. Averkov, et al.
Published: (2019-01-01)

Cutaneous Ulcer Caused by Apixaban Treatment Is Resolved after Replacement with Dabigatran
by: Alessandro Medoro, et al.
Published: (2022-05-01)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
by: Juseung Lee, et al.
Published: (2023-03-01)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
by: Alexander Cohen, et al.
Published: (2021-01-01)

Apixaban, a Novel Oral Anticoagulant, Use to Resolute Arterial Patency in Radial Artery Occlusion Due to Cardiac Catheterization; A Pilot Randomized Clinical Trial
by: Afshin Amirpour, et al.
Published: (2023-11-01)

Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs
by: Li Zhang, et al.
Published: (2021-05-01)

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art
by: S. R. Gilyarevsky
Published: (2022-07-01)

Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis
by: Jerrold H. Levy, et al.
Published: (2020-05-01)

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy
by: Sertan Özyalçın, et al.
Published: (2020-02-01)

PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION
by: A. V. Kryukov, et al.
Published: (2017-07-01)

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
by: Kim H, et al.
Published: (2023-08-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023-10-01)

DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT
by: D. А. Napalkov, et al.
Published: (2017-03-01)

GASTROINTESTINAL BLEEDING WITH THE USE OF NEW ORAL ANTICOAGULANTS: EPIDEMIOLOGY, RISK FACTORS, TREATMENT, AND PREVENTION
by: E. V. Moroz, et al.
Published: (2018-01-01)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
by: Ali Jaber, et al.
Published: (2022-10-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
by: Nicola Ferri, et al.
Published: (2022-05-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts
by: Arash Hedayat, et al.
Published: (2024-01-01)

Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results
by: Gualtiero Palareti, et al.
Published: (2022-03-01)

Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis
by: Joseph R. Shaw, et al.
Published: (2020-01-01)

A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants
by: Kulothungan Gunasekaran, et al.
Published: (2020-09-01)

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis
by: Chen I. Tseng, et al.
Published: (2023-02-01)

APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN
by: O. D. Ostroumova, et al.
Published: (2018-07-01)

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
by: Khalid Al Sulaiman, et al.
Published: (2022-05-01)